The Current Ratio as of September 2024 (TTM) for Cyteir Therapeutics, Inc. (CYT) is 21.89

According to Cyteir Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 21.89. This represents a change of -16.82% compared to the average of 26.31 of the last 4 quarters.

Cyteir Therapeutics, Inc. (CYT) Historical Current Ratio (quarterly & annually)

How has CYT Current Ratio performed in the past?

The mean historical Current Ratio of Cyteir Therapeutics, Inc. over the last ten years is 18.27. The current 21.89 Current Ratio has changed 11.88% with respect to the historical average. Over the past ten years (40 quarters), CYT's Current Ratio was at its highest in in the March 2023 quarter at 34.94. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Cyteir Therapeutics, Inc. (CYT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cyteir Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cyteir Therapeutics, Inc. (CYT) Average Current Ratio

How has CYT Current Ratio performed in the past?

The current Current Ratio of Cyteir Therapeutics, Inc. (CYT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cyteir Therapeutics, Inc. (CYT) Current Ratio vs. Peers

How is CYT’s Current Ratio compared to its peers?

Cyteir Therapeutics, Inc.’s Current Ratio is greater than Nuvation Bio Inc. (11.49), greater than Magenta Therapeutics, Inc. (14.64), greater than Neoleukin Therapeutics, Inc. (15.33), greater than Graphite Bio, Inc. (11.47), greater than Foghorn Therapeutics Inc. (5.69), greater than C4 Therapeutics, Inc. (5.09), greater than Prelude Therapeutics Incorporated (7.83), greater than Rezolute, Inc. (11.82), greater than Molecular Partners AG (14.58), greater than MediciNova, Inc. (18.24), greater than Anebulo Pharmaceuticals, Inc. (5.32), greater than Champions Oncology, Inc. (0.69), less than Eliem Therapeutics, Inc. (60.41), greater than HCW Biologics Inc. (0.10), greater than Monte Rosa Therapeutics, Inc. (6.56), greater than Nkarta, Inc. (15.91), greater than Lyell Immunopharma, Inc. (16.19), greater than Generation Bio Co. (7.42), greater than Sana Biotechnology, Inc. (5.20),

Build a custom stock screener for Cyteir Therapeutics, Inc. (CYT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyteir Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cyteir Therapeutics, Inc. (CYT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cyteir Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.